Erythromycin, an antibiotic drug used in COPD, could decrease the IL-17 and IL-23 levels in both the sputum and serum of COPD stage II-IV patients (94), which was further validated in mouse models to suppress Th17 response and promote Treg response (95). Here, IL17A is linked to chronic obstructive pulmonary disease.